Merck Exercised the Option for the Global Rights of Abbisko Therapeutics’s Pimicotinib
Press Releases
April 1, 2025

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics’s Pimicotinib

SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021),

bradford

The Bradford Era

Local & Social